Crinetics Pharmaceuticals announced the launch of the ACRO/TRUTH healthcare provider, HCP, educational website and initiative, the purpose of which is to spotlight the significant challenges and burdens many people living with acromegaly experience when managing their disease with the current standard-of-care, injectable somatostatin receptor ligands, SRLs. “People living with acromegaly still experience diminished quality of life due to their disease and to the limitations of the treatment options currently available to treat their disease,” said Alan Krasner, M.D., Chief Endocrinologist at Crinetics. “Crinetics is dedicated to bringing forward innovative products to better the lives of patients, and an integral part of that mission is bringing the patient perspective to the forefront.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
- Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
- Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 3 Best Stocks to Buy Now, 7/10/2024, According to Top Analysts
- Crinetics price target raised to $54 from $47 at JPMorgan
Questions or Comments about the article? Write to editor@tipranks.com